Fertility suppression on Testosterone Cypionate: Incidence, Severity, and Realistic Expectations

What testosterone cypionate does to sperm production

Cypionate is an oil-soluble ester of testosterone. Injected into muscle, it is absorbed slowly from the oil depot and split to free testosterone, with a half-life of about 8 days [1]. The Depo-Testosterone label gives the mechanism for the fertility effect directly: during exogenous androgen administration the body's own testosterone release is inhibited through feedback inhibition of pituitary LH, and at large doses of exogenous androgens sperm production may be suppressed through feedback inhibition of pituitary FSH [1].

The clearest measurement of this comes from a small randomized study. Twenty-nine healthy men received 200 mg testosterone enanthate weekly plus either saline or hCG every other day for 3 weeks. In the testosterone-plus-saline group, LH fell to 5% of baseline and FSH to 3%, and intratesticular testosterone fell 94%, from 1234 to 72 nmol/L [3]. Baseline serum testosterone in those men was 1.2% of the intratesticular concentration [3].

How common is it, and how severe?

The Depo-Testosterone label lists oligospermia as an adverse reaction that may occur at high dosages [1]. The same label lists testicular atrophy, subfertility and infertility among reactions reported in men who abuse anabolic androgenic steroids [1]. The Azmiro (cypionate) and Xyosted (enanthate) labels state that reduced fertility is seen in some men on testosterone replacement and that the effect on fertility may be irreversible.

The published recovery figures come from specific groups. The large recovery analysis studied healthy men using hormonal contraception regimens, not men receiving testosterone cypionate replacement for hypogonadism [2], and the men in fertility-clinic series are a selected group who presented with infertility [4][5]. That difference in who was studied is the main reason published percentages are hard to apply to an individual starting replacement therapy.

Recovery: what the numbers show

The largest recovery analysis pooled individual data from 30 studies of hormonal male contraception: 1,549 healthy eugonadal men, aged 18 to 51, whose sperm output was monitored monthly after treatment stopped. Median time for sperm concentration to return to 20 million/mL was 3.4 months. Recovery to 20 million/mL occurred in 67% by 6 months, 90% by 12 months, 96% by 16 months and 100% by 24 months. Faster recovery was associated with shorter-acting testosterone preparations, shorter treatment duration and higher baseline sperm concentration [2]. These men were healthy and eugonadal, not hypogonadal men on replacement therapy.

A clinic series gives the other end of the picture. Sixty-six men who presented with infertility after testosterone use stopped testosterone and began high-dose hCG plus a selective estrogen receptor modulator. Forty-six (70%) reached a total motile count above 5 million within 12 months. Only 64.8% of the azoospermic men reached that threshold, compared with 91.7% of the men who still had rare sperm in the ejaculate (cryptozoospermia). Older age and longer duration of testosterone use both predicted slower recovery [5].

The two datasets disagree on age: the contraception analysis found faster recovery in older men [2], while the 66-man clinic series found age consistently limited recovery [5].

If fertility matters: what has actually been tested

The Endocrine Society guideline recommends against starting testosterone therapy in men who are planning fertility in the near term [6].

The best-controlled evidence on hCG is the 29-man study described above. Adding hCG at 125, 250 or 500 IU every other day alongside 200 mg testosterone enanthate weekly maintained intratesticular testosterone in a dose-dependent way: 25% below baseline at 125 IU, 7% below at 250 IU and 26% above at 500 IU, with a linear dose response [3]. That was a 3-week study in healthy volunteers, so it shows maintenance of an intermediate marker, not sperm counts or pregnancy outcomes.

A retrospective series of 49 men with azoospermia or severe oligospermia (under 1 million/mL) while on exogenous testosterone used 3,000 units of hCG subcutaneously every other day, supplemented with clomiphene, tamoxifen, anastrozole or recombinant FSH. Spermatogenesis returned or improved in 47 men (95.9%) at an average of 4.6 months, with a mean first density of 22.6 million/mL, and there was no significant difference in recovery by type of testosterone used [4]. There was no control group.

Clomiphene is the other common option, used instead of exogenous testosterone to raise the body's own production. A 2013 review describes SERMs such as clomiphene citrate as effective for maintaining testosterone production and as a well-tolerated oral therapy, and concludes that clomiphene is a safe and effective therapy for men who want to maintain future potential fertility [7]. In a prospective study of 36 men with testosterone under 300 ng/dL taking 25 mg of clomiphene daily, mean testosterone rose from 247.6 to 610.0 ng/dL by the first follow-up at 4 to 6 weeks, with no side effects reported [8].